In 2005, Xyrem was acquired by Jazz Pharmaceuticals and was granted a second indication by the FDA for the treatment of EDS in patients with narcolepsy.
Xyrem was acquired by Jazz Pharmaceuticals. This was in 2005. Xyrem was granted a second indication by the FDA for the treatment of EDS in patients with narcolepsy. This was in 2005.